Artiva Biotherapeutics, Inc
Insiders
Last 12 monthsSales planned on beside the trades reported on , and whether each names a .
Planned ·
$1,250,229
12 notices · 166,169 sh
Oct 2025 to Oct 2026
Reported ·
$1,943,573
15 sales · 22 buys · $109.2M bought
Oct 2025 to Sep 2026
The two figures cover different periods.
6 of 15 reported sales carry the 10b5-1 box. Together they are 0.41% of the shares on issue.
under a no plan named▼ sale▲ buysize is dollars
Form 144 notices, newest first
2026-10-06FRED ASLAN, Chief Executive Officer$245,735
2026-09-08FRED ASLAN, Chief Executive Officer$262,171
Form 4, 2026-09-09: sold 23,429 at $10.92The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026. Form 4 ↗
2026-08-27SUBHASHIS BANERJEE, Chief Medical Officer$92,018
Form 4, 2026-08-31: sold 8,222 at $12.01The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. Form 4 ↗
2026-08-18SUBHASHIS BANERJEE, Chief Medical Officer$9,779
Form 4, 2026-08-19: sold 429 at $12.00The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 14, 2026. Form 4 ↗
2026-05-18Subhashis Banerjee, Chief Medical Officer$64,540
Form 4, 2026-05-19: sold 7,037 at $9.01The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax... Form 4 ↗
2026-05-18Heather Raymon, SVP, Research and Development$32,270
Form 4, 2026-05-19: sold 3,095 at $9.01The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax... Form 4 ↗
2026-05-18Fred Aslan, M.D., Chief Executive Officer$258,160
Form 4, 2026-05-19: sold 27,116 at $9.01The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax... Form 4 ↗
2026-05-18Christopher P. Horan, Chief Tech Operations Officer$69,150
Form 4, 2026-05-19: sold 7,002 at $9.01The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax... Form 4 ↗
2026-05-18Jennifer Bush, COO, CLO, Compliance Officer$82,980
Form 4, 2026-05-19: sold 8,790 at $9.01The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax... Form 4 ↗
2025-12-15FRED ASLAN, Chief Executive Officer$42,072
Form 4, 2025-12-15: sold 3,187 at $6.00Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024. Form 4 ↗
2025-11-17FRED ASLAN, Chief Executive Officer$20,719
Form 4, 2025-11-17: sold 6,375 at $3.38The reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024. Form 4 ↗